Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor

Yoshikazu Suzuki, Chie Sugiyama, Osamu Ohno, Kazuo Umezawa

Research output: Contribution to journalArticle

59 Citations (Scopus)


NF-κB is a transcription factor that induces inflammatory cytokines and anti-apoptotic proteins. We have designed a new NF-κB inhibitor based on the structure of the antibiotic epoxyquinomicin C. The designed compound, dehydroxymethylepoxyquinomicin (DHMEQ) was synthesized as a racemic form from 2,5-dimethoxyaniline through 5 steps. Application of racemic DHMEQ onto the chiral column (Chiralpak AD) directly gave enantiomeric DHMEQ after purification. (-)-DHMEQ was more potent than its enantiomer. (-)-DHMEQ was found to inhibit NF-κB activity and macrophage differentiation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in human monocyte THP-1 cells.

Original languageEnglish
Pages (from-to)7061-7066
Number of pages6
Issue number33
Publication statusPublished - 2004 Aug 9



  • Apoptosis
  • Inflammation
  • NF-κB
  • Nuclear transport
  • Optical resolution

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Cite this